



MAJOR DEAL TRANSACTIONS FOR PHARMA, BIOTECH AND HEALTHCARE

INNOVATION DAYS, Paris, October 5-6, 2015.

Jean-Claude Muller

Special Advisor, Innovation & International Relationship

2014-2015: Highlights

- Increasing number of hostile bids
- Great vitality of biotechs and start-up companies
- Remarquable increase of agreements related to combination therapies
- Substantial number of deals between pure technology players and biopharmaceutical companies
- Increasing number of agreement between Western and Chinese companies

Hostile Bids: Best of

- Pfizer over AstraZeneca
- AbbVie over Shire
- Shire over Actelion
- Shire over Baxalta
- AstraZeneca over Receptos
- Valeant over Salix
- Endo over Salix
- Valeant over Allergan
- Teva over Mylan
- Mylan over Perrigo

One example of biotech company vitality



- Viracor-IBT
- Diatherix
- Biomnis
- Bio-Acces
- Boston Heart Diagnostic
- Emory University Genetics Laboratory

Technology and BioPharma deals

- Google with:
 - Novartis (Ophthalmology)
 - AbbVie (Aging)
 - Sanofi (Diabetes)
 - Dexcom (Monitoring Devices)
- Panasonic with Bayer's diabetes business
- Janssen and Philips (Brain disorders)
- Fujifilm and Cellular Dynamics
- Teva with Microchip Biotech (Drug Delivery)

Western and Chinese Companies

- Ablynx and Edding Pharma
- Wuxi and NextCode
- Wuxi and University of Pennsylvania
- Eli Lilly and Innovent
- Illumina and China Burning Rock
- Chinese Consortium and Ambrx
- Shenzhen Hepalink and Cytovance
- Incyte and Jiangsu Hengrui